The Portuguese Medicine and Health Products Authority (Infarmed) has blocked the export of 28 critical medications this month, a regulatory intervention designed to prevent domestic shortages as these medicines face supply constraints. Patients relying on treatments for multiple sclerosis, attention-deficit hyperactivity disorder (ADHD), and several cancers are now affected by this protective measure aimed at preserving stock for domestic patients.
What's Been Banned
The export prohibition covers 28 medications identified as having medium-to-high public health impact following recent stock concerns. The list includes:
• Cancer therapies (treatments for bladder, ovarian, and breast cancer)
• Cardiac medications (including isosorbide mononitrate tablets for angina prevention)
• ADHD treatments and other psychiatric medications
• Multiple sclerosis therapies
The ban, formalized under Deliberação n.º 034/CD/2026 from the Circular Informativa n.º 039/CD/100.20.200 dated April 13, 2026, prohibits all manufacturers and distributors from exporting these medications. Violations are subject to enforcement action by Infarmed.
Why This Matters for Residents
If you or a family member depends on one of these 28 medications, the export ban serves as both a protection and a signal. The regulatory lock ensures that pharmacies and hospitals cannot legally ship these prescriptions abroad, theoretically preserving stock for Portuguese patients. However, the existence of the ban itself confirms that supply has become tight enough to warrant state intervention.
In practical terms, patients may experience:
• Potential dispensing limits: Pharmacies may provide smaller quantities per visit to extend available stock
• More frequent pharmacy visits: This could mean collecting refills more regularly than usual
• Possible substitutions: Healthcare providers may recommend alternative treatments if primary medications face availability constraints
For conditions like multiple sclerosis and ADHD, medication continuity is particularly important, as treatment interruptions can affect patient outcomes. Similarly, cancer patients require uninterrupted access to chemotherapy regimens.
Why Shortages Are Occurring
Medication shortages across Europe stem from multiple factors including production delays, quality control issues, and increased global demand. Portugal, like many EU nations, is experiencing tighter availability of certain essential medicines. These constraints have prompted regulatory responses to protect domestic supply.
Government Response
Infarmed monitors medication availability daily and maintains an updated list of export-restricted drugs. The agency coordinates with the European Medicines Agency (EMA) and other EU regulators to manage supply across the bloc. When medications appear on Portugal's banned export list, it indicates that domestic reserves have reached levels requiring protective measures.
The Portuguese government has implemented various measures to address medication availability, including pricing protections for essential and lower-cost medications. These interventions aim to stabilize access while the broader supply situation stabilizes.
What Patients Should Do
If you depend on one of these 28 medications:
• Check Infarmed's online portal under "Gestão da disponibilidade do medicamento" (Medication Availability Management) to confirm whether your medication is on the restricted list
• Speak with your pharmacist or healthcare provider if you experience any dispensing difficulties
• Request guidance from your doctor if you have concerns about access to your treatment
The export ban is designed to be a temporary protective measure while supply chains normalize. For the most current information on medication availability, consult Infarmed's official communications or speak with your healthcare provider.
